RNA editing: emerging from CRISPR’s shadow
Bio Pharma Dive
OCTOBER 22, 2024
Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start.
RNA Related Topics 
Wave sees RNA editing validation in early trial results
Bio Pharma Dive
OCTOBER 16, 2024
The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.
RNA 
358
358 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bayer partners with RNA drugmaker to develop new cancer therapies
Bio Pharma Dive
AUGUST 28, 2024
Under a collaboration with NextRNA Therapeutics, Bayer will access the biotech’s platform to target long, non-coding RNA interactions with small molecule drugs.
RNA 286
286 
Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney
Bio Pharma Dive
OCTOBER 7, 2024
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.
RNA 308
308 
Orna, a circular RNA specialist, acquires a buzzy startup
Bio Pharma Dive
MAY 23, 2024
After laying off staff late last year, Orna is expanding through the purchase of ReNAgade Therapeutics, which was built around technology designed to more effectively deliver RNA-based medicines.
RNA 294
294 
Roche partners with RNA editing biotech Ascidian
Bio Pharma Dive
JUNE 18, 2024
While the Swiss pharma recently pruned its neurology drug pipeline, it has shown interest in the possibilities of RNA-focused approaches like what Ascidian is exploring.
RNA 169
169 
Triastek and BioNTech to develop 3D-printed RNA therapeutics
Pharmaceutical Technology
JULY 24, 2024
BioNTech and Triastek have entered a research partnership focusing on the development of 3D-printed oral RNA therapeutics.
RNA 182
182 
Transforming CML patient monitoring with ICON’s innovative RNA-based NGS assay
Pharmaceutical Technology
OCTOBER 24, 2024
New RNA-based assays are helping. Chronic myeloid leukaemia – CML – is difficult to monitor and manage using traditional solutions.
RNA 130
130 RNA 130
130 
ESC 2024: Insights into RNA as therapeutic target and tool
Pharmaceutical Technology
SEPTEMBER 5, 2024
A panel of researchers gave presentations on the clinical evidence for the role of RNA in therapy for cardiovascular conditions.
RNA 130
130 
Gatehouse Bio and AstraZeneca to develop RNA therapeutics for heart failure
Pharmaceutical Technology
SEPTEMBER 9, 2022
US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). Gatehouse Bio is engaged in developing small RNA-based therapeutics using AI technology.
RNA 246
246 
Moderna founder's next big play in RNA raises $440 million
Bio Pharma Dive
AUGUST 30, 2021
Just a few months out of stealth mode, Laronde and its "endless RNA" technology have caught the attention of well-known investors like Fidelity, T. Rowe Price Associates and Invus.
RNA 350
350 RNA 350
350 
Drugging RNA with pills: small molecules for a big frontier
Bio Pharma Dive
SEPTEMBER 6, 2022
A handful of startups have formed in recent years with plans to target RNA with small molecules. Many have caught the attention of big drugmakers.
RNA 294
294 
Next-generation RNA technologies: making longer-lasting drugs with a broader reach
Bio Pharma Dive
AUGUST 23, 2022
At least 10 biotechnology startups are trying to use RNA molecules in new ways to make medicines. Here’s a look at where they stand.
RNA 332
332 
China-based biotech licenses Sanofi's RNA drug technology
Bio Pharma Dive
JULY 25, 2022
The Lilly-backed Rona Therapeutics gains rights to a platform for small interfering RNA, along with a slate of preclinical candidates aimed at targets in the liver and other tissues.
RNA 246
246 
Seattle institute lands $18m funding to develop RNA vaccine for chikungunya
Pharmaceutical Technology
AUGUST 3, 2023
AAHI is developing a novel RNA vaccine that overcomes manufacturing and storage limitations to increase accessibility.
RNA 244
244 
ReNAgade Therapeutics enters RNA therapy arena with $300m
Pharmaceutical Technology
MAY 23, 2023
ReNAgade Therapeutics has burst onto the RNA technology scene by announcing a $300m financing round. With its delivery system, Cambridge, Massachusetts-based biotech says it aims to “address major limitations in RNA therapeutics by enabling the delivery of RNA medicines to previously inaccessible tissues and cells in the body.”
RNA 147
147 
Moderna founder unveils new drug company focused on a different kind of RNA
Bio Pharma Dive
NOVEMBER 9, 2021
The biotech is researching how to make medicines from transfer RNA molecules. Encouraged by Moderna's success, Flagship Pioneering has been busy creating startups like Alltrna, which launched Tuesday.
RNA 359
359 
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
Bio Pharma Dive
APRIL 22, 2024
billion, is the latest research collaboration involving small molecule drugs that modify RNA. The deal, which could be worth up to $1.8
RNA 161
161 
Wave readies clinical testing for first RNA editing therapy
Bio Pharma Dive
SEPTEMBER 5, 2023
The biotech, one of several advancing RNA editing medicines, expects to obtain “proof-of-mechanism” data in patients with the inherited disorder alpha-1 antitrypsin deficiency by next year.
RNA 177
177 
Ascidian starts up with $50M and a twist on RNA editing
Bio Pharma Dive
OCTOBER 12, 2022
The startup, run by Translate Bio cofounder Romesh Subramanian, believes its RNA “exon editing” approach could have long-lasting effects without the risks that come with editing DNA.
RNA 258
258 
Ascidian and Roche to develop RNA therapies for neurological diseases
Pharmaceutical Technology
JUNE 19, 2024
Ascidian has entered a research partnership and licensing agreement with Roche to develop RNA therapies for neurological diseases.
RNA 130
130 
Self-amplifying RNA and vaccine innovation: getting from concept to clinic
Pharmaceutical Technology
MAY 28, 2024
Biomanufacturers using self-amplifying RNA, or saRNA, could enjoy significant advantages
RNA 162
162 
Moderna founder launches new biotech, looking to cure diseases through 'endless RNA'
Bio Pharma Dive
MAY 10, 2021
Laronde comes equipped with $50 million in funding from Flagship Pioneering and a goal to upend how diseases are treated with long-lasting RNA medicines.
RNA 351
351 
New UK intracellular drug delivery centre to support RNA development
Pharmaceutical Technology
JUNE 1, 2023
A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and therapeutics , as well as the development of innovative drug delivery technologies. It will focus on studying and developing new lipid nanoparticle (LNP) formulations for the delivery of RNA medicine.
Drug Delivery 242
242 
Roche joins startup Remix in bet on another way to drug RNA
Bio Pharma Dive
JANUARY 3, 2024
The deal is the third Roche has formed with startups developing pills that target RNA, following similar pacts with Arrakis and Ribometrix.
RNA 177
177 
Beam-linked startup launches with an eye on the next generation of RNA drugs
Bio Pharma Dive
SEPTEMBER 7, 2022
“We see a huge opportunity in the setting of RNA-based therapies to overcome some of the shortcomings that have been there with the first generation of RNA companies,” said former Alnylam CEO and Orbital Therapeutics co-founder John Maraganore.
RNA 230
230 
Amgen partners with Arrakis to develop drugs aimed at RNA
Bio Pharma Dive
JANUARY 11, 2022
Arrakis, a specialist in designing oral drugs that target RNA, will receive $75 million under the deal, which could be worth "several billion dollars" more.
RNA 258
258 
Beyond Covid-19: the disruptive potential of RNA-based therapeutics
Pharmaceutical Technology
MARCH 1, 2023
Further, the acceptance of new mRNA vaccines has rejuvenated activity within previously established categories of RNA therapeutics including lifesaving antisense technologies. These include antisense oligonucleotides (ASO), RNA interference (RNAi), and RNA aptamers.
RNA 147
147 
Silence Therapeutics gets grant for compound for rna interference therapy in treating liver disease
Pharmaceutical Technology
JUNE 11, 2024
Discover the groundbreaking patent by Silence Therapeutics Plc for a compound revolutionizing RNA interference therapy. Learn how formula (II) is paving the way for targeted treatment of liver disease and genetic disorders.
RNA 130
130 
As Arrowhead falters, lungs remain a tough target for RNA drugs
Bio Pharma Dive
JULY 6, 2021
The biotech's decision to pause testing of a cystic fibrosis drug is the latest reminder of the difficulty of delivering RNA medicines into the lungs.
RNA 300
300 
Silence Therapeutics gets grant for compound for rna interference therapy in liver disease
Pharmaceutical Technology
APRIL 22, 2024
Discover how Silence Therapeutics' patented compound for RNA interference therapy targets liver disease with precision. Learn about the specific chemical formula and potential therapeutic benefits outlined in the recently granted patent.
RNA 130
130 RNA 130
130 
Flamingo gets grant from VLAIO to accelerate RNA-focused oncology portfolio
Pharmaceutical Technology
JUNE 16, 2023
from Flanders Innovation & Entrepreneurship (VLAIO) to further advance its oncology portfolio targeting RNA. It will also support the firm’s preclinical effort on the long non-coding RNA (LncRNA) programme, FTX-001, that targets MALAT-1. Flamingo Therapeutics has received a research grant of €1.7m
RNA 173
173 
Daiichi Sankyo and Depixus partner to accelerate RNA-targeted drug discovery
Pharmaceutical Technology
DECEMBER 13, 2023
Daiichi Sankyo plans to leverage the French startup’s technology to develop its RNA-targeted therapeutics pipeline.
RNA 147
147 
Orbital raises $270m investment for advancement of RNA medicines
Pharmaceutical Technology
APRIL 27, 2023
Orbital Therapeutics has raised $270m in a Series A round led by ARCH Venture Partners to advance a portfolio of programmable RNA therapeutics. Orbital will use the new funding to increase the application of RNA-based medicines for use in the fields of new vaccines, immunomodulation and protein replacement.
RNA 130
130 
ReNAgade debuts with $300M and an ‘all-in-one’ system for delivering RNA drugs
Bio Pharma Dive
MAY 23, 2023
Staffed by many former Alnylam and Moderna employees, the startup is developing technologies that could be useful in a variety of RNA drugmaking methods.
RNA 189
189 
Venture capital pours more money into RNA medicines with the launch of Replicate
Bio Pharma Dive
SEPTEMBER 8, 2021
The company, which focuses on self-replicating RNA, comes equipped with $40 million from Apple Tree Partners and a stamp of approval from the former research head at Biogen.
RNA 271
271 
Ethris and Heqet team up for RNA-based therapeutic development
Pharmaceutical Technology
NOVEMBER 13, 2023
Heqet Therapeutics and Ethris have collaborated to develop RNA-based therapeutics to treat cardiovascular conditions.
RNA 130
130 
Moving RNA Therapeutics Beyond the Liver
BioSpace
DECEMBER 3, 2023
From the skin to the lungs to the central nervous system, biotech companies are making progress toward delivering RNA therapeutics to multiple targets throughout the body. But challenges remain.
RNA 117
117 RNA 117
117 
Wave surges on first RNA editing data in humans
pharmaphorum
OCTOBER 16, 2024
Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD)
RNA 72
72 
J&J to explore RNA reprogramming with Remix research deal
Bio Pharma Dive
FEBRUARY 17, 2022
The agreement with the Cambridge-based startup is the latest to reflect growing large pharma company interest in targeting RNA with small molecules.
RNA 195
195 
Novo Nordisk agrees $1.1bn takeover of RNA biotech Cardior
pharmaphorum
MARCH 25, 2024
billion, adding expertise in RNA therapeutics and a heart failure therapy in mid-stage trials. Novo Nordisk has agreed to buy Cardior Pharmaceuticals for $1.1
RNA 122
122 
ReciBioPharm’s Edita Botonjic-Sehic, on analytics, AI, and continuous RNA manufacturing
BioPharma Reporter
JULY 4, 2024
RNA therapeutics have emerged as a transformative approach to treating many conditions, but the industry still typically relies on inefficient batch manufacturing methods.
RNA 98
98 
Scaling up RNA-LNPs: Strategies for successful and consistent clinical manufacturing
Pharmaceutical Technology
NOVEMBER 2, 2023
While things may have slowed down a little since the rapid approvals of the COVID-19 vaccines, the excitement around RNA-LNP is still going strong.
RNA 130
130 
Ochre Bio raises funds to develop RNA therapies for liver diseases
Pharmaceutical Technology
OCTOBER 11, 2022
Biotechnology company Ochre Bio has raised $30m in a Series A financing round to develop RNA therapies for chronic liver diseases. It also intends to turn the insights from its research into RNA-based drug candidates, and they will be tested in human livers at the company’s recently opened ‘Liver ICUs’ in the US.
RNA 130
130 
Let's personalize your content